Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial

Martín-Martorell, Paloma; Roselló, Susana; Rodríguez-Braun, Edith; Chirivella, Isabel; Bosch, Ana; Cervantes, A.

doi:10.1038/sj.bjc.6604530

Cited by 49 publications

(26 citation statements)

References 12 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the PFS/OS of group A was statistically significantly longer than in group B. Our response rate and PFS/OS of group B were compatible with the results of several previous studies from Western countries (Pfeiffer et al, 2007;Martin-Martorell et al, 2008). In group A, the response rate and PFS/OS were similar when compared to the results of several previous studies from Western countries (Folprecht et al, 2006), but were significantly better than group B, and those findings are vital for mCRC patients for the administration of the firstline or second/third-line cetuximab-combination chemotherapy.…”

Section: Discussionsupporting

confidence: 81%

Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens

Chen¹,

Tsai²,

Kuo³

et al. 2011

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Cetuximab, a monoclonal antibody targeting epidermal growth factor receptor, has proven to be efficient in the treatment of metastatic colorectal cancer. We made a prospective study of the efficacy and toxicities of cetuximab-combination first-line (FOLFOX4) versus second/third-line (FOLFIRI) chemotherapy in 98 KRAS wildtype patients who had metastatic colorectal cancer. Wild-type KRAS had been identified by direct sequencing. Associations between clinical response/progression-free survival/overall survival/toxicities and cetuximab-combination chemotherapy timing were evaluated. The overall response rate was significantly higher for first-line treatment than for second/third-line treatment (relative risk = 1.707, 95% confidence interval = 1.121-2.598). Both progression-free survival and overall survival indicated significantly longer survival of first-line treatment than second/third-line treatment patients. This study is a validation of a molecular analysis of KRAS wild-type status for the prediction of response to cetuximab-combination chemotherapy for metastatic colorectal cancer patients; its predictive role was less prominent in the second/thirdline than in the first-line treatment patients.

show abstract

Section: Discussionsupporting

confidence: 81%

Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens

Chen¹,

Tsai²,

Kuo³

et al. 2011

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Cetuximab q1w and q2w have shown similar pharmacokinetic, pharmacodynamic and safety results [11,12] . Additionally, the efficacy of the q2w regimen has also been confirmed in previous studies [13][14][15] .…”

supporting

confidence: 64%

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

et al. 2010

View full text Add to dashboard Cite

Background: We gathered data from multiple institutions on the cetuximab regimen of patients with metastatic colorectal cancer. Methods: 126 patients from 19 centers were included from July 2006 to July 2007 in this prospective non-controlled study. Irinotecan-refractory metastatic colorectal cancer patients with Karnofsky ≧70 received cetuximab 500 mg/m² every 2 weeks (q2w) in combination with irinotecan 180 mg/m² q2w until disease progression or unacceptable toxicity. The primary endpoint was the progression-free rate at 12 weeks. Results: Median age was 65 years; 65.9% male; colon/rectum 64.3/34.1%; Karnofsky status ≤80/≧90% in 45.3/54.7% of the patients. The progression-free rate was 42.7 (95% CI 32.8–52.6) and 22.4% (95% CI 14.2–30.7) at 12 and 24 weeks, respectively. The main grade 3 or 4 toxicities were: diarrhea 13.5% and acne-like rash 10.3%. No grade 3 or 4 infusional or allergic reactions were reported. Conclusions: The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen.

show abstract

“…Panitumumab is approved for use on a biweekly dosing schedule and cetuximab is approved for a weekly infusion regimen with a loading dose, and these remain the standard. Some recent reports suggest the possibility of a simplified cetuximab monotherapy regimen dosed every 2 weeks, whereas other studies have demonstrated the clinical activity of cetuximab biweekly regimens when used in combination with irinotecan [42][43][44]. Furthermore, clinical studies have demonstrated efficacy in patients treated with panitumumab using a 3-week dosing schedule [45,46].…”

Section: Discussionmentioning

confidence: 99%

Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

2009

View full text Add to dashboard Cite

Over the past 10 years there has been a significant increase in the armamentarium of agents available for use in the treatment of advanced colorectal cancer (CRC). Among these new agents are two monoclonal antibodies targeting the epidermal growth factor receptor (EGFR): cetuximab, a mousehuman chimeric monoclonal antibody, and panitumumab, a fully human monoclonal antibody. Both are approved as monotherapy for the treatment of chemotherapy-refractory advanced CRC. Cetuximab is also indicated for use in combination with irinotecan. Here, we review 10 reports of phase II and III clinical studies of patients treated with panitumumab or cetuximab monotherapy. The clinical trials demonstrate similar efficacy profiles for advanced CRC patients treated with panitumumab and cetuximab monotherapy, with some differences in their adverse event profiles. In addition, the recent results of retrospective tumor KRAS gene mutational analyses in CRC patients treated with anti-EGFR monotherapy are reviewed. Data from the clinical trials reviewed here clearly demonstrate that anti-EGFR monotherapy is an effective treatment modality for patients with chemotherapy-refractory advanced CRC. The Oncologist

show abstract

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial

Cited by 49 publications

References 12 publications

Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens

Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

Anti–Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

Contact Info

Product

Resources

About